<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Community Hosp Intern Med Perspect</journal-id><journal-id journal-id-type="iso-abbrev">J Community Hosp Intern Med Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2124</journal-id><journal-id journal-id-type="pmc-domain">jchimp</journal-id><journal-title-group><journal-title>Journal of Community Hospital Internal Medicine Perspectives</journal-title></journal-title-group><issn pub-type="epub">2000-9666</issn><publisher><publisher-name>Greater Baltimore Medical Center</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11745179</article-id><article-id pub-id-type="pmcid-ver">PMC11745179.1</article-id><article-id pub-id-type="pmcaid">11745179</article-id><article-id pub-id-type="pmcaiid">11745179</article-id><article-id pub-id-type="pmid">39839162</article-id><article-id pub-id-type="doi">10.55729/2000-9666.1420</article-id><article-id pub-id-type="publisher-id">jchim-14-06-035</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Review of Attributes and Outcomes of Hospitalized Patients with Alcohol Withdrawal</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Desai</surname><given-names initials="HR">Harsh R.</given-names></name><xref rid="af1-jchim-14-06-035" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hyland</surname><given-names initials="JS">Joan S.</given-names></name><xref rid="af2-jchim-14-06-035" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paulos</surname><given-names initials="E">Erica</given-names></name><xref rid="af3-jchim-14-06-035" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shaw</surname><given-names initials="E">Eric</given-names></name><xref rid="af4-jchim-14-06-035" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parisio-Poldiak</surname><given-names initials="N">Nayda</given-names></name><xref rid="af3-jchim-14-06-035" ref-type="aff">c</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Patel</surname><given-names initials="M">Maulikkumar</given-names></name><xref rid="af3-jchim-14-06-035" ref-type="aff">c</xref><xref rid="af4-jchim-14-06-035" ref-type="aff">d</xref><xref rid="c1-jchim-14-06-035" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-jchim-14-06-035">
<label>a</label>Trident Regional Medical Center, Charleston, SC 29406, 
<country>USA</country></aff><aff id="af2-jchim-14-06-035">
<label>b</label>Florida Orange Park Hospital, Florida, Orange Park, FL 32073, 
<country>USA</country></aff><aff id="af3-jchim-14-06-035">
<label>c</label>HCA Healthcare, Nashville, TN 37203, 
<country>USA</country></aff><aff id="af4-jchim-14-06-035">
<label>d</label>Memorial Health University Medical Center, Savannah, GA 31404, 
<country>USA</country></aff><author-notes><corresp id="c1-jchim-14-06-035"><label>*</label>Corresponding author. E-mail addresses: <email>harsh.desai@hcahealthcare.com</email> (H.R. Desai), <email>shannster12@gmail.com</email> (J.S. Hyland), <email>erica.paulos@hcahealthcare.com</email> (E. Paulos), eric. <email>shaw@hcahealthcare.com</email> (E. Shaw), <email>nayda.parisiopoldiak@hcahealthcare.com</email> (N. Parisio-Poldiak), <email>Maulikkumar.Patel@hcahealthcare.com</email> (M. Patel).</corresp></author-notes><pub-date publication-format="electronic" date-type="collection"><year>2024</year></pub-date><pub-date publication-format="electronic" date-type="pub"><day>02</day><month>11</month><year>2024</year></pub-date><volume>14</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">479999</issue-id><fpage>35</fpage><lpage>42</lpage><history><date date-type="received"><day>04</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>01</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>21</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-29 01:25:36.520"><day>29</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Greater Baltimore Medical Center</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jchim-14-06-035.pdf"/><abstract><sec><title>Background</title><p>Alcohol abuse leads to millions of hospital admissions each year in the United States. Alcohol withdrawal syndrome (AWS) is associated with several serious complications, including seizures, delirium tremens, and death. Benzodiazepines have been the mainstay of treatment for hospitalized patients with alcohol withdrawal.</p></sec><sec><title>Objective</title><p>To compare hospital length of stay (LOS) among different protocols for the management of AWS in hospitalized patients.</p></sec><sec><title>Methods</title><p>We conducted a retrospective study of 49,125 adult patients admitted over 4 years (2018&#8211;2022) to HCA Healthcare hospitals across the USA with a diagnosis of alcohol use disorder or alcohol withdrawal. Hospital LOS was the primary outcome examined across various treatment groups (chlordiazepoxide, diazepam, gabapentin, lorazepam, phenobarbital). Secondary outcomes included the initial Clinical Institute Withdrawal Assessment (CIWA) score, intensive care unit (ICU) admission rates, readmission rates, and mortality.</p></sec><sec><title>Results</title><p>The average age of patients admitted was 48 years, and the majority (72%) were White males. Lorazepam was the most frequently used protocol and was associated with the lowest LOS (3.96 days). Patients treated with lorazepam had relatively higher initial CIWA scores. Only 11% of patients were admitted to the ICU during their hospitalization, and only 2% were intubated or ventilated. There were no 30-day readmissions, and less than 1% of patients admitted with a diagnosis of AWS died. Other protocols, such as gabapentin, diazepam, phenobarbital, and chlordiazepoxide, were less commonly used and had variable impacts on the outcomes studied.</p></sec><sec><title>Conclusions</title><p>The results of this retrospective study support lorazepam as an effective treatment for AWS management. Future research should focus on comparing the effectiveness of alcohol withdrawal assessment tools in patients with baseline psychiatric disorders.</p></sec></abstract><kwd-group><kwd>Alcohol withdrawal</kwd><kwd>CIWA</kwd><kwd>Benzodiazepine</kwd><kwd>Phenobarbital</kwd><kwd>Lorazepam</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><label>1.</label><title>Introduction</title><p>Alcohol is a commonly abused substance in the United States that results in millions of hospital admissions each year requiring clinical management.<xref rid="b1-jchim-14-06-035" ref-type="bibr">1</xref> Alcohol withdrawal syndrome (AWS) increases hospital length of stay (LOS), serious complications such as seizures and delirium tremens, and ultimately mortality.<xref rid="b2-jchim-14-06-035" ref-type="bibr">2</xref> The Clinical Institute Withdrawal Assessment (CIWA-Ar) is an assessment tool to evaluate symptoms of alcohol withdrawal and guide AWS management in the hospital setting.<xref rid="b3-jchim-14-06-035" ref-type="bibr">3</xref> Various treatment protocols have been used for managing AWS and their use has improved clinical outcomes.<xref rid="b4-jchim-14-06-035" ref-type="bibr">4</xref></p><p>The mainstay of treatment of most hospital AWS protocols has been benzodiazepines and phenobarbital. Studies have reported variable outcomes in effectiveness and tolerability when compared against each other. Few studies have suggested that phenobarbital compared to benzodiazepines decreases intensive care unit (ICU) admission, ICU or hospital LOS, all-cause readmission, ED visits, delirium tremens, medication adverse effects, and mechanical ventilation rates.<xref rid="b5-jchim-14-06-035" ref-type="bibr">5</xref>&#8211;<xref rid="b8-jchim-14-06-035" ref-type="bibr">8</xref> Conversely, other researchers did not demonstrate any difference comparing phenobarbital to benzodiazepines on the rate of ICU admission, LOS in ICU or hospital, severity of symptoms, complications/adverse effects, intubation rate, and alcohol-related readmission.<xref rid="b7-jchim-14-06-035" ref-type="bibr">7</xref>&#8211;<xref rid="b11-jchim-14-06-035" ref-type="bibr">11</xref> One study combined phenobarbital with lorazepam and found a reduced LOS.<xref rid="b12-jchim-14-06-035" ref-type="bibr">12</xref> The type of AWS protocol varies among hospitals, whether it involves fixed versus symptom-triggered dosing, or front-loading versus intermittent dosing.<xref rid="b2-jchim-14-06-035" ref-type="bibr">2</xref>,<xref rid="b13-jchim-14-06-035" ref-type="bibr">13</xref>,<xref rid="b14-jchim-14-06-035" ref-type="bibr">14</xref> Several researchers have also tried other adjuncts for AWS treatment, including baclofen, dexmedetomidine, chlordiazepoxide, and gabapentin. Again, the results have demonstrated shorter LOS, reduced delirium tremens, or no difference.<xref rid="b15-jchim-14-06-035" ref-type="bibr">15</xref>&#8211;<xref rid="b18-jchim-14-06-035" ref-type="bibr">18</xref> However, a recent meta-analysis comparing benzodiazepine with non-benzodiazepine treatment reported no significant difference in CIWA-Ar scores during the course of AWS.<xref rid="b19-jchim-14-06-035" ref-type="bibr">19</xref></p><p>Interestingly, the symptoms of AWS can overlap with underlying neurological problems such as dementia, delirium, psychiatric conditions, and traumatic brain injury, which can complicate CIWA-Ar and alcohol withdrawal management.<xref rid="b4-jchim-14-06-035" ref-type="bibr">4</xref>,<xref rid="b20-jchim-14-06-035" ref-type="bibr">20</xref>,<xref rid="b21-jchim-14-06-035" ref-type="bibr">21</xref> Additionally, a patient&#8217;s baseline laboratory values, vital signs, or previous history of AWS could serve as important predictors for the severity of AWS.<xref rid="b22-jchim-14-06-035" ref-type="bibr">22</xref>,<xref rid="b23-jchim-14-06-035" ref-type="bibr">23</xref> The findings from existing prospective and retrospective studies have been limited by sample size, focus on a specific AWS protocol, and consideration of only certain primary and secondary outcomes. Thus, we performed a retrospective study using the robust Enterprise Data Warehouse (EDW) data set across the HCA Healthcare sites to identify risk factors for AWS and compare the effectiveness of different AWS protocols and associated outcomes. We anticipate that findings from our study will help identify optimal AWS treatment strategies. Our retrospective cohort study aims to compare LOS among various drug protocols used for the management of patients admitted with AWS.</p></sec><sec sec-type="methods"><label>2.</label><title>Methods</title><sec><title>2.1. Sample or participants</title><p>The patient population included admissions across all HCA Healthcare facilities from July 31, 2018, to July 31, 2022. Study subjects were selected based on the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes. Inclusion criteria included all patients older than 18 years of age with a diagnosis of alcohol use disorder or alcohol withdrawal syndrome. We excluded patients under 18 years of age and those with allergies to phenobarbital, benzodiazepines, or other anti-epileptics studied (<xref rid="s1-jchim-14-06-035" ref-type="supplementary-material">Supplementary Figure 1</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp" ext-link-type="uri">https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp</ext-link>)). The data for this retrospective study were abstracted through the HCA Healthcare Enterprise Data Warehouse (EDW) using the aforementioned ICD-10 codes (<xref rid="s1-jchim-14-06-035" ref-type="supplementary-material">Supplementary Table 1</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp" ext-link-type="uri">https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp</ext-link>)). We initially analyzed eight different protocols (phenobarbital, lorazepam, oxazepam, chlordiazepoxide, midazolam, diazepam, gabapentin, baclofen), but later decided to focus on five of the most commonly used protocols. Therefore, we did not include baclofen, midazolam, and oxazepam in our final analysis due to relatively small sample size (<xref rid="s1-jchim-14-06-035" ref-type="supplementary-material">Supplementary Table 2</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp" ext-link-type="uri">https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp</ext-link>)).</p></sec><sec><title>2.2. Data for quantitative outcomes</title><p>The primary outcome of focus was LOS among five different protocols studied. The secondary outcomes studied included initial CIWA score, admission triage, discharge disposition, ICU admission, intubation/ventilation rate, alcohol withdrawal-related complications (such as seizures and pneumonia), medication-related adverse effects, and readmission rates/30-day emergency department visits after discharge. The phenobarbital group was the comparison group in our study. The study received an IRB exempt determination and approval (2024-467).</p></sec><sec><title>2.3. Statistical analysis</title><p>All statistical analyses were performed using the statistical software RStudio. SQL was used to extract the data. Categorical variables were summarized using frequencies and percentages, while descriptive statistics for continuous variables included mean and standard deviation. Patients were categorized and measured as a categorical variable based on which protocol the patients were placed on. Comparative analyses were performed using the <italic toggle="yes">t</italic>-test or Mann&#8211;Whitney U test for continuous variables, or cross-tabulations with Pearson chi-square test or Fisher&#8217;s exact test for categorical variables, as appropriate, depending upon the type of variable and data normality. All inferential statistical tests were two-tailed and used a tolerance for nominal type 1 error (alpha) of 0.05. The box-and-whisker plot was created using RStudio software.</p></sec></sec><sec sec-type="results"><label>3.</label><title>Results</title><p>Our study examined 49,125 patients admitted for AWS from July 2018 to 2022 at HCA Healthcare hospitals across the USA. We first analyzed the demographic data of the patients studied. The ratio of males to females was approximately 3:1, and it remained constant across various AWS protocols (<xref rid="t1-jchim-14-06-035" ref-type="table">Table 1</xref>). The mean age of the patient population studied was 48 &#177; 12.9 years. A significant number of Caucasians (79%) were included in the sample, compared to 9% African Americans and 10% mixed ethnicity. The frequencies of Native Americans, Hispanics, and Asians were less than 1%. Among the admitted patients, the majority had triage scores (based on Emergency Severity Index, <xref rid="s1-jchim-14-06-035" ref-type="supplementary-material">Supplementary Table 3</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp" ext-link-type="uri">https://scholarlycommons.gbmc.org/cgi/editor.cgi?article=1420&amp;window=additional_files&amp;context=jchimp</ext-link>)), of either level 2 (emergent, 36%) or level 3 (urgent, 26%). However, only 2% of the sampled population was triaged at level 1 (resuscitation), and less than 1% was triaged as levels 4 and 5. The triage score was not recorded for 36% of the admitted patients.</p><p>Among the five protocols we analyzed, lorazepam was the agent of choice for 75.5% of the total number of patients admitted for AWS. Gabapentin (12.10%), diazepam (5.51%), phenobarbital (4.75%), and chlordiazepoxide (2.08%) protocols were less commonly used (<xref rid="t1-jchim-14-06-035" ref-type="table">Table 1</xref>). The average LOS across all protocols was 4.14 days (<xref rid="t2-jchim-14-06-035" ref-type="table">Table 2</xref>; <xref rid="f1-jchim-14-06-035" ref-type="fig">Fig. 1</xref>). The LOS for the diazepam group (mean 4.08 days, p &lt; 0.001) and the lorazepam group (mean 3.96 days, p &lt; 0.001) was significantly shorter compared to that of the phenobarbital group (mean 4.69 days; comparison group). In contrast, gabapentin had a significantly greater LOS (mean 5.03 days, p = 0.001) compared to phenobarbital. However, chlordiazepoxide (mean 4.57 days, p = 0.018) did not show a significant difference in LOS compared to that of phenobarbital.</p><p>We used the other secondary endpoints as surrogates to demonstrate that overall patient outcomes were not negatively impacted. The average initial CIWA score was 5.60 (<xref rid="t3-jchim-14-06-035" ref-type="table">Table 3</xref>). The initial CIWA scores for lorazepam (5.94, p &lt; 0.001), diazepam (5.69, p &lt; 0.001), chlordiazepoxide (4.72, p &lt; 0.001), and gabapentin (4.22, p &lt; 0.001) were higher than the CIWA score of 3.54 for the comparison group phenobarbital. Lorazepam was associated with relatively higher CIWA scores and lower LOS. We also looked at initial vitals, such as the Glasgow coma scale (GCS), heart rate, and respirations; however, due to missing data fields for many patients, an in-depth analysis of these values was not performed (<xref rid="t3-jchim-14-06-035" ref-type="table">Table 3</xref>).</p><p>We further reviewed the number of ICU admissions and the rate of intubation or ventilation (<xref rid="t4-jchim-14-06-035" ref-type="table">Table 4</xref>). The rate of ICU admissions was 10.60%. The highest rate of ICU admissions was among patients using the lorazepam protocol (4334 patients, or 11.68%), representing 8.82% of the total patient population admitted for AWS. ICU admissions were less prevalent for protocols using diazepam (293 patients, or 10.83%), phenobarbital (201 patients, or 8.61%), gabapentin (377 patients, or 6.34%), and chlordiazepoxide (1 patient). Similarly, the overall intubation or ventilation rate was 1.55%, more frequent for patients on lorazepam protocol (616 patients, 1.65%), and a slightly higher rate for patients on diazepam protocol (59 patients, 2.18%).</p><p>We also examined other outcomes such as discharge disposition, readmission rates, and complications (<xref rid="t4-jchim-14-06-035" ref-type="table">Table 4</xref>). The discharge disposition variable considered whether a patient was deceased at the time of discharge. The overall percentage of deceased patients at discharge was 0.47%. Death was somewhat more frequent among patients on lorazepam protocol (197 patients, or 0.53%) and was also notable in other groups, including diazepam (0.41%), gabapentin (0.30%), chlordiazepoxide (0.29%), and phenobarbital (0.13%). Notably, none of the protocol groups had any 30-day readmissions. We also looked at alcohol withdrawal-related complications including medication-related adverse effects, neurological or metabolic complications, etc. We observed a higher prevalence of complications in the following systems: gastrointestinal (13.63%), hematological (7.41%), and neurological (4.64%). The specifics of the complications experienced were not considered as part of the study. Among the patient population we studied, less than 2% had underlying neurological disorders such as Parkinson&#8217;s, epilepsy, dementia, or traumatic brain injury. Notably, a relatively higher proportion of patients in the phenobarbital group experienced alcohol-induced complications or had pre-existing neurological conditions. Since only a small proportion of patients studied experienced complications, a statistical comparison could not be drawn.</p></sec><sec sec-type="discussion"><label>4.</label><title>Discussion</title><p>Our study found that management of AWS with lorazepam is associated with a lower LOS and higher initial CIWA scores compared to other commonly used drug protocols we studied. We observed that the number of ICU admissions, intubation rates, and mortality were relatively higher in the lorazepam group, with no difference in readmission rates or alcohol-induced complications. To our knowledge, this is the first study to examine such a large national sample using the HCA Healthcare database.</p><p>Patients admitted to the hospital with alcohol use disorder frequently experience AWS, which can be potentially life-threatening and may cause seizures or delirium tremens. Therefore, early recognition and appropriate management are crucial to reducing the risk of complications. Various therapeutic strategies exist for managing AWS; however, there are no standardized nationwide guidelines. Benzodiazepines are commonly used as first-line therapies, but several alternative options have been proposed with varying effectiveness. A lorazepam-based protocol for AWS is most frequently used across HCA Healthcare hospitals in the United States. Studies comparing lorazepam with other benzodiazepines, such as diazepam and chlordiazepoxide,<xref rid="b24-jchim-14-06-035" ref-type="bibr">24</xref>&#8211;<xref rid="b26-jchim-14-06-035" ref-type="bibr">26</xref> have revealed comparable effects. Phenobarbital is emerging as an alternative to benzodiazepines.<xref rid="b6-jchim-14-06-035" ref-type="bibr">6</xref>,<xref rid="b11-jchim-14-06-035" ref-type="bibr">11</xref> Systematic review, meta-analysis,<xref rid="b27-jchim-14-06-035" ref-type="bibr">27</xref> cohort studies,<xref rid="b28-jchim-14-06-035" ref-type="bibr">28</xref> and retrospective studies<xref rid="b7-jchim-14-06-035" ref-type="bibr">7</xref>,<xref rid="b10-jchim-14-06-035" ref-type="bibr">10</xref>,<xref rid="b29-jchim-14-06-035" ref-type="bibr">29</xref>,<xref rid="b30-jchim-14-06-035" ref-type="bibr">30</xref> have not shown any significant difference between AWS management with phenobarbital and benzodiazepines. Our study favors the use of lorazepam, as it significantly reduces LOS compared to phenobarbital. The differences in the neurochemistry and pharmacokinetics of phenobarbital make it an effective alternative for treating AWS, particularly for patients with contraindications to benzodiazepines or those at risk of severe AWS.<xref rid="b5-jchim-14-06-035" ref-type="bibr">5</xref> Another alternative is the use of gabapentin, which, at high doses, has been associated with a lower hospital LOS, lower mean CIWA-Ar scores, and reduced use of benzodiazepines.<xref rid="b15-jchim-14-06-035" ref-type="bibr">15</xref>,<xref rid="b31-jchim-14-06-035" ref-type="bibr">31</xref> For patients who may not respond to first-line therapies such as benzodiazepines, other adjunctive strategies have been studied, including dexmedetomidine, <xref rid="b32-jchim-14-06-035" ref-type="bibr">32</xref>&#8211;<xref rid="b35-jchim-14-06-035" ref-type="bibr">35</xref> propofol,<xref rid="b36-jchim-14-06-035" ref-type="bibr">36</xref>,<xref rid="b37-jchim-14-06-035" ref-type="bibr">37</xref> levetiracetam,<xref rid="b38-jchim-14-06-035" ref-type="bibr">38</xref> and ketamine<xref rid="b13-jchim-14-06-035" ref-type="bibr">13</xref>,<xref rid="b39-jchim-14-06-035" ref-type="bibr">39</xref> though these have produced mixed results and raised concerns about adverse effects.</p><p>There are several assessment tools for withdrawal symptoms, but the CIWA scale has been the most validated. Our study showed that admission CIWA scores were relatively higher for the lorazepam group compared to other protocols. Since the lorazepam group had a shorter LOS, this suggests that lorazepam may be an effective agent for AWS, regardless of varying initial CIWA scores. Other agents may be helpful when lorazepam or other benzodiazepines are not effective or are contraindicated. Several studies have noted that a symptom-triggered approach resulted in a reduction in overall benzodiazepine usage and duration.<xref rid="b40-jchim-14-06-035" ref-type="bibr">40</xref>,<xref rid="b41-jchim-14-06-035" ref-type="bibr">41</xref> Clinicians have also employed other strategies, such as fixed dosing or front loading. For example, an early and focused approach with front loading of diazepam in the first 24 h resulted in a reduced hospital LOS.<xref rid="b42-jchim-14-06-035" ref-type="bibr">42</xref> When researchers compared a fixed tapering dose of phenobarbital to a fixed dose of benzodiazepines in trauma and general medical ward, patients had decreased incidence of AWS without significant difference in LOS.<xref rid="b7-jchim-14-06-035" ref-type="bibr">7</xref>,<xref rid="b10-jchim-14-06-035" ref-type="bibr">10</xref> Additionally, lorazepam-based AWS protocols are relatively standardized compared to phenobarbital, which can have varying dosing among hospitals. Our study cannot distinguish which dosing strategies or regimens were commonly utilized, and this remains a possible avenue for further investigation.</p><p>The retrospective design of our study presents several limitations that should be acknowledged. Currently, symptom-triggered management of AWS using the CIWA-Ar is the standard of care. Similarly, our work only considered CIWA-Ar, as it is a standardized and validated scale commonly used across the hospitals in the United States. Many studies have focused on other scales, such as the Sedation agitation scale<xref rid="b43-jchim-14-06-035" ref-type="bibr">43</xref> or the 5-point scale.<xref rid="b44-jchim-14-06-035" ref-type="bibr">44</xref>,<xref rid="b45-jchim-14-06-035" ref-type="bibr">45</xref> However, the nature of our data allowed us to examine only the initial CIWA-Ar scores, and data were unavailable for some patients. Additionally, we were unable to track how CIWA scores varied during admission. There are limitations to using the CIWA-Ar scale, as patients who lack cognitive or communicative abilities&#8212;such as those with delirium or encephalopathy&#8212;may not be suitable candidates. Furthermore, if a provider chooses to use a fixed dosing approach for AWS, the CIWA scale may not be administered. This study did not address the effectiveness of other scales, which could be a focus for future research.</p><p>Secondly, the choice of AWS protocol can vary based on individual hospital guidelines or a physician&#8217;s preference, introducing variability and inherent bias. Our study was unable to identify the factors influencing a physician&#8217;s choice of protocol, such as co-morbidities, physician training, prior patient history, or institution policy. We also could not assess whether other adjuvant agents were used or what dosing regimens were employed, both of which could influence the outcomes. Nevertheless, the results of this study align with previous literature, highlighting the widespread use of lorazepam and its effectiveness in AWS management. It is also worth noting that our study did not include three protocols in the final analysis, as they accounted for less than 2% of combined use. This exclusion could potentially affect the reproducibility and generalizability of our findings. Lastly, the retrospective nature of the study depends on the quality of data available in the database, and there is a possibility of missed cases or inaccurate diagnoses that could potentially confound the results.</p><p>In summary, our study shows that lorazepam is a commonly used and effective management approach for AWS in hospitalized patients. Its association with relatively lower LOS can positively influence hospital reimbursement rates and reduce the total healthcare cost per patient.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><supplementary-material id="s1-jchim-14-06-035" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jchim-14-06-035-s001.docx" id="d67e407" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>H.R.D. and J.S.H designed the project, interpreted the data, and wrote and edited the manuscript; E.P. analyzed the data; N.P.P. and E.S. provided input with design and data interpretation; M.P. supervised the project, designed the project, interpreted the data, and critically edited the manuscript. All authors read and approved the final version of the manuscript. M.P. is responsible for the integrity of the work as a whole.</p></ack><fn-group><fn id="fn1-jchim-14-06-035"><p><bold>Ethics information:</bold> This research activity was conducted in compliance with the corporate requirements and determined to be exempt from Institutional Review Board (IRB) oversight in accordance with current regulations and institutional policy.</p></fn><fn id="fn2-jchim-14-06-035" fn-type="COI-statement"><p><bold>Conflict of interest:</bold> The authors declare that they have no competing financial or other conflicts of interests.</p></fn><fn id="fn3-jchim-14-06-035"><p><bold>Financial support:</bold> The authors did not receive any funding for the present study.</p></fn><fn id="fn4-jchim-14-06-035"><p><bold>Disclaimer:</bold> This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-jchim-14-06-035"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasha</surname><given-names>AK</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadiq</surname><given-names>S</given-names></name><name name-style="western"><surname>Fairbanks</surname><given-names>J</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S</given-names></name></person-group><article-title>Substance use disorders: diagnosis and management for hospitalists</article-title><source>J Community Hosp Intern Med Perspect</source><year>2020</year><volume>10</volume><issue>2</issue><fpage>117</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1080/20009666.2020.1742495</pub-id><pub-id pub-id-type="pmid">32850046</pub-id><pub-id pub-id-type="pmcid">PMC7425622</pub-id></mixed-citation></ref><ref id="b2-jchim-14-06-035"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>E</given-names></name><name name-style="western"><surname>Daly</surname><given-names>C</given-names></name></person-group><article-title>Clinical management of the alcohol withdrawal syndrome</article-title><source>Addict Abingdon Engl</source><year>2022</year><volume>117</volume><issue>3</issue><fpage>804</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1111/add.15647</pub-id><pub-id pub-id-type="pmid">34288186</pub-id></mixed-citation></ref><ref id="b3-jchim-14-06-035"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attilia</surname><given-names>F</given-names></name><name name-style="western"><surname>Perciballi</surname><given-names>R</given-names></name><name name-style="western"><surname>Rotondo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alcohol withdrawal syndrome: diagnostic and therapeutic methods</article-title><source>Riv Psichiatr</source><year>2018</year><volume>53</volume><issue>3</issue><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1708/2925.29413</pub-id><pub-id pub-id-type="pmid">29912213</pub-id></mixed-citation></ref><ref id="b4-jchim-14-06-035"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrokh</surname><given-names>S</given-names></name><name name-style="western"><surname>Roels</surname><given-names>C</given-names></name><name name-style="western"><surname>Owusu</surname><given-names>KA</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Cook</surname><given-names>AM</given-names></name></person-group><article-title>Alcohol withdrawal syndrome in neurocritical care unit: assessment and treatment challenges</article-title><source>Neurocritical Care</source><year>2021</year><volume>34</volume><issue>2</issue><fpage>593</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1007/s12028-020-01061-8</pub-id><pub-id pub-id-type="pmid">32794143</pub-id></mixed-citation></ref><ref id="b5-jchim-14-06-035"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>JA</given-names></name><name name-style="western"><surname>Curran</surname><given-names>BM</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>WA</given-names></name><name name-style="western"><surname>Harnica</surname><given-names>HM</given-names></name></person-group><article-title>Adjunctive phenobarbital for alcohol withdrawal syndrome: a focused literature review</article-title><source>Ann Pharmacother</source><year>2021</year><volume>55</volume><issue>12</issue><fpage>1515</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1177/1060028021999821</pub-id><pub-id pub-id-type="pmid">33678057</pub-id></mixed-citation></ref><ref id="b6-jchim-14-06-035"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tidwell</surname><given-names>WP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>TL</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>JD</given-names></name><name name-style="western"><surname>Canonico</surname><given-names>AE</given-names></name><name name-style="western"><surname>Webber</surname><given-names>AJ</given-names></name></person-group><article-title>Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol</article-title><source>Am J Crit Care Off Publ Am Assoc Crit-Care Nurses</source><year>2018</year><volume>27</volume><issue>6</issue><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.4037/ajcc2018745</pub-id><pub-id pub-id-type="pmid">30385536</pub-id></mixed-citation></ref><ref id="b7-jchim-14-06-035"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nejad</surname><given-names>S</given-names></name><name name-style="western"><surname>Nisavic</surname><given-names>M</given-names></name><name name-style="western"><surname>Larentzakis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phenobarbital for acute alcohol withdrawal management in surgical trauma patients-A retrospective comparison study</article-title><source>Psychosomatics</source><year>2020</year><volume>61</volume><issue>4</issue><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.psym.2020.01.008</pub-id><pub-id pub-id-type="pmid">32199629</pub-id></mixed-citation></ref><ref id="b8-jchim-14-06-035"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawa</surname><given-names>F</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>L</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>B</given-names></name><etal/></person-group><article-title>Phenobarbital versus lorazepam for management of alcohol withdrawal syndrome: a retrospective cohort study</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>2</issue><fpage>e13282</fpage><pub-id pub-id-type="doi">10.7759/cureus.13282</pub-id><pub-id pub-id-type="pmid">33728215</pub-id><pub-id pub-id-type="pmcid">PMC7949711</pub-id></mixed-citation></ref><ref id="b9-jchim-14-06-035"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lam</surname><given-names>SW</given-names></name></person-group><article-title>Phenobarbital and symptom-triggered lorazepam versus lorazepam alone for severe alcohol withdrawal in the intensive care unit</article-title><source>Alcohol Fayettev N</source><year>2020</year><volume>82</volume><fpage>23</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2019.07.004</pub-id><pub-id pub-id-type="pmid">31326601</pub-id></mixed-citation></ref><ref id="b10-jchim-14-06-035"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nisavic</surname><given-names>M</given-names></name><name name-style="western"><surname>Nejad</surname><given-names>SH</given-names></name><name name-style="western"><surname>Isenberg</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Use of phenobarbital in alcohol withdrawal management - a retrospective comparison study of phenobarbital and benzodiazepines for acute alcohol withdrawal management in general medical patients</article-title><source>Psychosomatics</source><year>2019</year><volume>60</volume><issue>5</issue><fpage>458</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.psym.2019.02.002</pub-id><pub-id pub-id-type="pmid">30876654</pub-id></mixed-citation></ref><ref id="b11-jchim-14-06-035"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dewey</surname><given-names>BN</given-names></name><name name-style="western"><surname>Jarrell</surname><given-names>DH</given-names></name><name name-style="western"><surname>Vadiei</surname><given-names>N</given-names></name><name name-style="western"><surname>Patanwala</surname><given-names>AE</given-names></name></person-group><article-title>Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED</article-title><source>Am J Emerg Med</source><year>2019</year><volume>37</volume><issue>7</issue><fpage>1313</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2018.10.007</pub-id><pub-id pub-id-type="pmid">30414743</pub-id></mixed-citation></ref><ref id="b12-jchim-14-06-035"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibarra</surname><given-names>F</given-names></name></person-group><article-title>Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal</article-title><source>Am J Emerg Med</source><year>2020</year><volume>38</volume><issue>2</issue><fpage>178</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2019.01.053</pub-id><pub-id pub-id-type="pmid">30744913</pub-id></mixed-citation></ref><ref id="b13-jchim-14-06-035"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>P</given-names></name><name name-style="western"><surname>McDowell</surname><given-names>M</given-names></name><name name-style="western"><surname>Ebisu</surname><given-names>R</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>T</given-names></name><name name-style="western"><surname>Toerne</surname><given-names>T</given-names></name></person-group><article-title>Adjunctive use of ketamine for benzodiazepine-resistant severe alcohol withdrawal: a retrospective evaluation</article-title><source>J Med Toxicol Off J Am Coll Med Toxicol</source><year>2018</year><volume>14</volume><issue>3</issue><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s13181-018-0662-8</pub-id><pub-id pub-id-type="pmcid">PMC6097970</pub-id><pub-id pub-id-type="pmid">29748926</pub-id></mixed-citation></ref><ref id="b14-jchim-14-06-035"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ammar</surname><given-names>AA</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kassab</surname><given-names>HS</given-names></name><name name-style="western"><surname>Becher</surname><given-names>RD</given-names></name></person-group><article-title>Phenobarbital monotherapy for the management of alcohol withdrawal syndrome in surgical-trauma patients</article-title><source>Ann Pharmacother</source><year>2021</year><volume>55</volume><issue>3</issue><fpage>294</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1177/1060028020949137</pub-id><pub-id pub-id-type="pmid">32830517</pub-id></mixed-citation></ref><ref id="b15-jchim-14-06-035"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>AR</given-names></name><name name-style="western"><surname>Carrasquillo</surname><given-names>L</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>J</given-names></name><name name-style="western"><surname>Nounou</surname><given-names>MI</given-names></name><name name-style="western"><surname>Naut</surname><given-names>ER</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>D</given-names></name></person-group><article-title>High-dose gabapentin for the treatment of severe alcohol withdrawal syndrome: a retrospective cohort analysis</article-title><source>Pharmacotherapy</source><year>2019</year><volume>39</volume><issue>9</issue><fpage>881</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1002/phar.2309</pub-id><pub-id pub-id-type="pmid">31278761</pub-id></mixed-citation></ref><ref id="b16-jchim-14-06-035"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixit</surname><given-names>D</given-names></name><name name-style="western"><surname>Endicott</surname><given-names>J</given-names></name><name name-style="western"><surname>Burry</surname><given-names>L</given-names></name><etal/></person-group><article-title>Management of acute alcohol withdrawal syndrome in critically ill patients</article-title><source>Pharmacotherapy</source><year>2016</year><volume>36</volume><issue>7</issue><fpage>797</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1002/phar.1770</pub-id><pub-id pub-id-type="pmid">27196747</pub-id></mixed-citation></ref><ref id="b17-jchim-14-06-035"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woods</surname><given-names>AD</given-names></name><name name-style="western"><surname>Giometti</surname><given-names>R</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>SM</given-names></name></person-group><article-title>The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review</article-title><source>JBI Database Syst Rev Implement Rep</source><year>2015</year><volume>13</volume><issue>1</issue><fpage>224</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.11124/jbisrir-2015-1602</pub-id><pub-id pub-id-type="pmid">26447017</pub-id></mixed-citation></ref><ref id="b18-jchim-14-06-035"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LN</given-names></name></person-group><article-title>Baclofen for alcohol withdrawal</article-title><source>Cochrane Database Syst Rev</source><year>2019</year><day>11</day><volume>6</volume><issue>11</issue><pub-id pub-id-type="doi">10.1002/14651858.CD008502.pub6</pub-id><pub-id pub-id-type="pmcid">PMC6831488</pub-id><pub-id pub-id-type="pmid">31689723</pub-id></mixed-citation></ref><ref id="b19-jchim-14-06-035"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prib&#233;k</surname><given-names>IK</given-names></name><name name-style="western"><surname>Kov&#225;cs</surname><given-names>I</given-names></name><name name-style="western"><surname>K&#225;d&#225;r</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Evaluation of the course and treatment of alcohol withdrawal syndrome with the clinical Institute withdrawal assessment for alcohol - revised: A systematic review-based meta-analysis</article-title><source>Drug Alcohol Depend</source><year>2021</year><volume>220</volume><fpage>108536</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108536</pub-id><pub-id pub-id-type="pmid">33503582</pub-id></mixed-citation></ref><ref id="b20-jchim-14-06-035"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wojnar</surname><given-names>M</given-names></name><name name-style="western"><surname>Wasilewski</surname><given-names>D</given-names></name><name name-style="western"><surname>Zmigrodzka</surname><given-names>I</given-names></name><name name-style="western"><surname>Grobel</surname><given-names>I</given-names></name></person-group><article-title>Age-related differences in the course of alcohol withdrawal in hospitalized patients</article-title><source>Alcohol Alcohol</source><year>2001</year><volume>36</volume><issue>6</issue><fpage>577</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1093/alcalc/36.6.577</pub-id><pub-id pub-id-type="pmid">11704625</pub-id></mixed-citation></ref><ref id="b21-jchim-14-06-035"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>W</given-names></name><name name-style="western"><surname>Truong</surname><given-names>P</given-names></name><name name-style="western"><surname>Sima</surname><given-names>AP</given-names></name><name name-style="western"><surname>Hupe</surname><given-names>J</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J</given-names></name><name name-style="western"><surname>Ebadi</surname><given-names>A</given-names></name></person-group><article-title>Impact of traumatic brain injury on clinical Institute withdrawal assessment use in trauma patients: a descriptive study</article-title><source>Pharm Manag PM R</source><year>2021</year><volume>13</volume><issue>2</issue><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1002/pmrj.12385</pub-id><pub-id pub-id-type="pmid">32304351</pub-id></mixed-citation></ref><ref id="b22-jchim-14-06-035"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodson</surname><given-names>CM</given-names></name><name name-style="western"><surname>Clark</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>IS</given-names></name></person-group><article-title>Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis</article-title><source>Alcohol Clin Exp Res</source><year>2014</year><volume>38</volume><issue>10</issue><fpage>2664</fpage><lpage>2677</lpage><pub-id pub-id-type="doi">10.1111/acer.12529</pub-id><pub-id pub-id-type="pmid">25346507</pub-id></mixed-citation></ref><ref id="b23-jchim-14-06-035"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steel</surname><given-names>TL</given-names></name><name name-style="western"><surname>Afshar</surname><given-names>M</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>S</given-names></name><etal/></person-group><article-title>Research needs for inpatient management of severe alcohol withdrawal syndrome: an official American thoracic society research statement</article-title><source>Am J Respir Crit Care Med</source><year>2021</year><volume>204</volume><issue>7</issue><fpage>e61</fpage><lpage>e87</lpage><pub-id pub-id-type="doi">10.1164/rccm.202108-1845ST</pub-id><pub-id pub-id-type="pmid">34609257</pub-id><pub-id pub-id-type="pmcid">PMC8528516</pub-id></mixed-citation></ref><ref id="b24-jchim-14-06-035"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheuermeyer</surname><given-names>FX</given-names></name><name name-style="western"><surname>Miles</surname><given-names>I</given-names></name><name name-style="western"><surname>Lane</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Lorazepam versus diazepam in the management of emergency department patients with alcohol withdrawal</article-title><source>Ann Emerg Med</source><year>2020</year><volume>76</volume><issue>6</issue><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2020.05.029</pub-id><pub-id pub-id-type="pmid">32736932</pub-id></mixed-citation></ref><ref id="b25-jchim-14-06-035"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>March</surname><given-names>KL</given-names></name><name name-style="western"><surname>Twilla</surname><given-names>JD</given-names></name><name name-style="western"><surname>Reaves</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients</article-title><source>Alcohol Fayettev N</source><year>2019</year><volume>81</volume><fpage>56</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2019.05.008</pub-id><pub-id pub-id-type="pmid">31176787</pub-id></mixed-citation></ref><ref id="b26-jchim-14-06-035"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramanujam</surname><given-names>R</given-names></name><name name-style="western"><surname>LP</surname></name><name name-style="western"><surname>GS</surname></name><name name-style="western"><surname>Thimmaiah</surname><given-names>RS</given-names></name></person-group><article-title>A comparative study of the clinical efficacy and safety of Lorazepam and chlordiazepoxide in alcohol dependence syndrome</article-title><source>J Clin Diagn Res JCDR</source><year>2015</year><volume>9</volume><issue>3</issue><fpage>FC10</fpage><lpage>FC13</lpage><pub-id pub-id-type="doi">10.7860/JCDR/2015/11887.5678</pub-id><pub-id pub-id-type="pmcid">PMC4413079</pub-id><pub-id pub-id-type="pmid">25954631</pub-id></mixed-citation></ref><ref id="b27-jchim-14-06-035"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourmand</surname><given-names>A</given-names></name><name name-style="western"><surname>AlRemeithi</surname><given-names>R</given-names></name><name name-style="western"><surname>Kartiko</surname><given-names>S</given-names></name><name name-style="western"><surname>Bronstein</surname><given-names>D</given-names></name><name name-style="western"><surname>Tran</surname><given-names>QK</given-names></name></person-group><article-title>Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: a systematic review and meta-analysis</article-title><source>Am J Emerg Med</source><year>2023</year><volume>69</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2023.04.002</pub-id><pub-id pub-id-type="pmid">37060631</pub-id></mixed-citation></ref><ref id="b28-jchim-14-06-035"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askgaard</surname><given-names>G</given-names></name><name name-style="western"><surname>Hallas</surname><given-names>J</given-names></name><name name-style="western"><surname>Fink-Jensen</surname><given-names>A</given-names></name><name name-style="western"><surname>Molander</surname><given-names>AC</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A</given-names></name></person-group><article-title>Phenobarbital compared to benzodiazepines in alcohol withdrawal treatment: a register-based cohort study of subsequent benzodiazepine use, alcohol recidivism and mortality</article-title><source>Drug Alcohol Depend</source><year>2016</year><volume>161</volume><fpage>258</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.02.016</pub-id><pub-id pub-id-type="pmid">26922279</pub-id></mixed-citation></ref><ref id="b29-jchim-14-06-035"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pistore</surname><given-names>A</given-names></name><name name-style="western"><surname>Penney</surname><given-names>S</given-names></name><name name-style="western"><surname>Bryce</surname><given-names>R</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>B</given-names></name></person-group><article-title>A retrospective evaluation of phenobarbital versus benzodiazepines for treatment of alcohol withdrawal in a regional Canadian emergency department</article-title><source>Alcohol Fayettev N</source><year>2022</year><volume>102</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.alcohol.2022.05.001</pub-id><pub-id pub-id-type="pmid">35569673</pub-id></mixed-citation></ref><ref id="b30-jchim-14-06-035"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kehoe</surname><given-names>J</given-names></name><name name-style="western"><surname>Sankoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Mintzer</surname><given-names>D</given-names></name><name name-style="western"><surname>Taub</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaucher</surname><given-names>KA</given-names></name></person-group><article-title>Benzodiazepines vs barbiturates for alcohol withdrawal: analysis of 3 different treatment protocols</article-title><source>Am J Emerg Med</source><year>2019</year><volume>37</volume><issue>4</issue><fpage>733</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/j.ajem.2019.01.002</pub-id><pub-id pub-id-type="pmid">30685075</pub-id></mixed-citation></ref><ref id="b31-jchim-14-06-035"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>M</given-names></name><name name-style="western"><surname>Udeh</surname><given-names>E</given-names></name><name name-style="western"><surname>Burak</surname><given-names>M</given-names></name></person-group><article-title>Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal</article-title><source>Am J Drug Alcohol Abuse</source><year>2019</year><volume>45</volume><issue>4</issue><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1080/00952990.2019.1602136</pub-id><pub-id pub-id-type="pmid">30990361</pub-id></mixed-citation></ref><ref id="b32-jchim-14-06-035"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>LR</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>BR</given-names></name><name name-style="western"><surname>Goodberlet</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Marino</surname><given-names>KK</given-names></name><name name-style="western"><surname>Lupi</surname><given-names>KE</given-names></name><name name-style="western"><surname>DeGrado</surname><given-names>JR</given-names></name></person-group><article-title>Evaluation of dexmedetomidine as an adjunct to phenobarbital for alcohol withdrawal in critically ill patients</article-title><source>J Intensive Care Med</source><year>2023</year><volume>38</volume><issue>6</issue><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1177/08850666231152837</pub-id><pub-id pub-id-type="pmid">36703284</pub-id></mixed-citation></ref><ref id="b33-jchim-14-06-035"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanderWeide</surname><given-names>LA</given-names></name><name name-style="western"><surname>Foster</surname><given-names>CJ</given-names></name><name name-style="western"><surname>MacLaren</surname><given-names>R</given-names></name><name name-style="western"><surname>Kiser</surname><given-names>TH</given-names></name><name name-style="western"><surname>Fish</surname><given-names>DN</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>SW</given-names></name></person-group><article-title>Evaluation of early dexmedetomidine addition to the standard of care for severe alcohol withdrawal in the ICU: a retrospective controlled cohort study</article-title><source>J Intensive Care Med</source><year>2016</year><volume>31</volume><issue>3</issue><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1177/0885066614554908</pub-id><pub-id pub-id-type="pmid">25326428</pub-id></mixed-citation></ref><ref id="b34-jchim-14-06-035"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Rossinen</surname><given-names>J</given-names></name><name name-style="western"><surname>Alho</surname><given-names>H</given-names></name><name name-style="western"><surname>Harjola</surname><given-names>VP</given-names></name></person-group><article-title>Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium</article-title><source>Eur J Emerg Med Off J Eur Soc Emerg Med</source><year>2013</year><volume>20</volume><issue>6</issue><fpage>425</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1097/MEJ.0b013e32835c53b3</pub-id><pub-id pub-id-type="pmid">23247391</pub-id></mixed-citation></ref><ref id="b35-jchim-14-06-035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>K</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>AE</given-names></name></person-group><article-title>Use of propofol plus dexmedetomidine in patients experiencing severe alcohol withdrawal in the intensive care unit</article-title><source>J Clin Pharmacol</source><year>2020</year><volume>60</volume><issue>4</issue><fpage>439</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1002/jcph.1539</pub-id><pub-id pub-id-type="pmid">31663139</pub-id></mixed-citation></ref><ref id="b36-jchim-14-06-035"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohraby</surname><given-names>R</given-names></name><name name-style="western"><surname>Attridge</surname><given-names>RL</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>DW</given-names></name></person-group><article-title>Use of propofol-containing versus benzodiazepine regimens for alcohol withdrawal requiring mechanical ventilation</article-title><source>Ann Pharmacother</source><year>2014</year><volume>48</volume><issue>4</issue><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1177/1060028013515846</pub-id><pub-id pub-id-type="pmid">24436457</pub-id></mixed-citation></ref><ref id="b37-jchim-14-06-035"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brotherton</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>EP</given-names></name><name name-style="western"><surname>Kloss</surname><given-names>HG</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>DA</given-names></name></person-group><article-title>Propofol for treatment of refractory alcohol withdrawal syndrome: a review of the literature</article-title><source>Pharmacotherapy</source><year>2016</year><volume>36</volume><issue>4</issue><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1002/phar.1726</pub-id><pub-id pub-id-type="pmid">26893017</pub-id></mixed-citation></ref><ref id="b38-jchim-14-06-035"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youland</surname><given-names>KM</given-names></name><name name-style="western"><surname>Miller</surname><given-names>RF</given-names></name><name name-style="western"><surname>Mahoney</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Borgert</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gundrum</surname><given-names>JD</given-names></name></person-group><article-title>Levetiracetam as adjunctive therapy for acute alcohol withdrawal syndrome in hospitalized patients</article-title><source>J Clin Psychopharmacol</source><year>2014</year><volume>34</volume><issue>6</issue><fpage>704</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000209</pub-id><pub-id pub-id-type="pmid">25144138</pub-id></mixed-citation></ref><ref id="b39-jchim-14-06-035"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pizon</surname><given-names>AF</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Benedict</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Adjunct ketamine use in the management of severe ethanol withdrawal</article-title><source>Crit Care Med</source><year>2018</year><volume>46</volume><issue>8</issue><fpage>e768</fpage><lpage>e771</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000003204</pub-id><pub-id pub-id-type="pmid">29742583</pub-id></mixed-citation></ref><ref id="b40-jchim-14-06-035"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holleck</surname><given-names>JL</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>N</given-names></name><name name-style="western"><surname>Gunderson</surname><given-names>CG</given-names></name></person-group><article-title>Symptom-triggered therapy for alcohol withdrawal syndrome: a systematic review and meta-analysis of randomized controlled trials</article-title><source>J Gen Intern Med</source><year>2019</year><volume>34</volume><issue>6</issue><fpage>1018</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1007/s11606-019-04899-7</pub-id><pub-id pub-id-type="pmid">30937668</pub-id><pub-id pub-id-type="pmcid">PMC6544709</pub-id></mixed-citation></ref><ref id="b41-jchim-14-06-035"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachdeva</surname><given-names>A</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>M</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>SN</given-names></name></person-group><article-title>A comparative study of fixed tapering dose regimen versus symptom-triggered regimen of lorazepam for alcohol detoxification</article-title><source>Alcohol Alcohol Oxf Oxfs</source><year>2014</year><volume>49</volume><issue>3</issue><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agt181</pub-id><pub-id pub-id-type="pmid">24407777</pub-id></mixed-citation></ref><ref id="b42-jchim-14-06-035"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JA</given-names></name><name name-style="western"><surname>Duby</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Cocanour</surname><given-names>CS</given-names></name></person-group><article-title>Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome</article-title><source>Clin Toxicol Phila Pa</source><year>2019</year><volume>57</volume><issue>7</issue><fpage>624</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1080/15563650.2018.1542701</pub-id><pub-id pub-id-type="pmid">30729859</pub-id></mixed-citation></ref><ref id="b43-jchim-14-06-035"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>S</given-names></name><name name-style="western"><surname>Grgurich</surname><given-names>P</given-names></name><name name-style="western"><surname>Tulolo</surname><given-names>A</given-names></name><etal/></person-group><article-title>A symptom-triggered benzodiazepine protocol utilizing SAS and CIWA-Ar scoring for the treatment of alcohol withdrawal syndrome in the critically ill</article-title><source>Ann Pharmacother</source><year>2017</year><volume>51</volume><issue>2</issue><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1177/1060028016672036</pub-id><pub-id pub-id-type="pmid">27733668</pub-id></mixed-citation></ref><ref id="b44-jchim-14-06-035"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rastegar</surname><given-names>DA</given-names></name><name name-style="western"><surname>Applewhite</surname><given-names>D</given-names></name><name name-style="western"><surname>Alvanzo</surname><given-names>AAH</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>C</given-names></name><name name-style="western"><surname>Niessen</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ES</given-names></name></person-group><article-title>Development and implementation of an alcohol withdrawal protocol using a 5-item scale, the Brief Alcohol Withdrawal Scale (BAWS)</article-title><source>Subst Abuse</source><year>2017</year><volume>38</volume><issue>4</issue><fpage>394</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1080/08897077.2017.1354119</pub-id><pub-id pub-id-type="pmid">28699845</pub-id></mixed-citation></ref><ref id="b45-jchim-14-06-035"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindner</surname><given-names>BK</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>VT</given-names></name><name name-style="western"><surname>Kruer</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Evaluation of the brief alcohol withdrawal scale protocol at an academic medical center</article-title><source>J Addiction Med</source><year>2019</year><volume>13</volume><issue>5</issue><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000510</pub-id><pub-id pub-id-type="pmid">30741834</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="f1-jchim-14-06-035" orientation="portrait"><label>Fig. 1</label><caption><p>The primary outcome, length of stay (LOS), is represented as a box and whisker plot for each alcohol withdrawal protocol.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jchim-14-06-035f1.jpg"/></fig><table-wrap position="float" id="t1-jchim-14-06-035" orientation="portrait"><label>Table 1</label><caption><p>Outlines the basic demographic information obtained from the Enterprise Data Warehouse (EDW) for all drug protocols analyzed.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">CDP</th><th valign="top" align="left" rowspan="1" colspan="1">DZP</th><th valign="top" align="left" rowspan="1" colspan="1">GBP</th><th valign="top" align="left" rowspan="1" colspan="1">LRZ</th><th valign="top" align="left" rowspan="1" colspan="1">PB</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">46.00 &#177; 12.65</td><td valign="top" align="left" rowspan="1" colspan="1">47.58 &#177; 12.60</td><td valign="top" align="left" rowspan="1" colspan="1">50.17 &#177; 12.55</td><td valign="top" align="left" rowspan="1" colspan="1">47.91 &#177; 12.94</td><td valign="top" align="left" rowspan="1" colspan="1">46.01 &#177; 12.44</td><td valign="top" align="left" rowspan="1" colspan="1">48.03 &#177; 12.88</td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1"><bold>Sex</bold>
<xref rid="tfn3-jchim-14-06-035" ref-type="table-fn">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">278 (27.23)</td><td valign="top" align="left" rowspan="1" colspan="1">723 (26.72)</td><td valign="top" align="left" rowspan="1" colspan="1">1702 (28.62)</td><td valign="top" align="left" rowspan="1" colspan="1">9763 (26.30)</td><td valign="top" align="left" rowspan="1" colspan="1">511 (21.89)</td><td valign="top" align="left" rowspan="1" colspan="1">12,977 (26.42)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">743 (72.77)</td><td valign="top" align="left" rowspan="1" colspan="1">1975 (72.99)</td><td valign="top" align="left" rowspan="1" colspan="1">4196 (70.56)</td><td valign="top" align="left" rowspan="1" colspan="1">26,999 (72.74)</td><td valign="top" align="left" rowspan="1" colspan="1">1532 (65.64)</td><td valign="top" align="left" rowspan="1" colspan="1">35,445 (72.15)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Not Assigned</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.30)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (0.82)</td><td valign="top" align="left" rowspan="1" colspan="1">355 (0.96)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">703 (1.43)</td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1"><bold>Race</bold>
<xref rid="tfn4-jchim-14-06-035" ref-type="table-fn">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">White</td><td valign="top" align="left" rowspan="1" colspan="1">752 (73.65)</td><td valign="top" align="left" rowspan="1" colspan="1">2175 (80.38)</td><td valign="top" align="left" rowspan="1" colspan="1">4893 (82.28)</td><td valign="top" align="left" rowspan="1" colspan="1">29,169 (78.59)</td><td valign="top" align="left" rowspan="1" colspan="1">1456 (62.38)</td><td valign="top" align="left" rowspan="1" colspan="1">38,445 (78.26)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">African American</td><td valign="top" align="left" rowspan="1" colspan="1">93 (9.11)</td><td valign="top" align="left" rowspan="1" colspan="1">234 (8.65)</td><td valign="top" align="left" rowspan="1" colspan="1">527 (8.86)</td><td valign="top" align="left" rowspan="1" colspan="1">3210 (8.64)</td><td valign="top" align="left" rowspan="1" colspan="1">421 (18.04)</td><td valign="top" align="left" rowspan="1" colspan="1">4485 (9.13)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Asian</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.69)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (0.48)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (0.49)</td><td valign="top" align="left" rowspan="1" colspan="1">232 (0.63)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (0.43)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (0.59)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.04)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.05)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (0.07)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">30 (0.06)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Native</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.78)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (0.52)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (0.18)</td><td valign="top" align="left" rowspan="1" colspan="1">91 (0.25)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (0.17)</td><td valign="top" align="left" rowspan="1" colspan="1">128 (0.26)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Multi/Other</td><td valign="top" align="left" rowspan="1" colspan="1">160 (16.67)</td><td valign="top" align="left" rowspan="1" colspan="1">261 (9.65)</td><td valign="top" align="left" rowspan="1" colspan="1">435 (7.31)</td><td valign="top" align="left" rowspan="1" colspan="1">4034 (10.87)</td><td valign="top" align="left" rowspan="1" colspan="1">152 (6.51)</td><td valign="top" align="left" rowspan="1" colspan="1">5042 (10.26)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Not Assigned</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.30)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (0.82)</td><td valign="top" align="left" rowspan="1" colspan="1">356 (0.96)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">704 (1.43)</td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1"><bold>Triage Score</bold>
<xref rid="tfn4-jchim-14-06-035" ref-type="table-fn">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1 - Resuscitation</td><td valign="top" align="left" rowspan="1" colspan="1">16 (1.57)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (2.22)</td><td valign="top" align="left" rowspan="1" colspan="1">101 (1.70)</td><td valign="top" align="left" rowspan="1" colspan="1">637 (1.72)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (0.73)</td><td valign="top" align="left" rowspan="1" colspan="1">831 (1.69)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2 - Emergent</td><td valign="top" align="left" rowspan="1" colspan="1">452 (44.27)</td><td valign="top" align="left" rowspan="1" colspan="1">967 (35.74)</td><td valign="top" align="left" rowspan="1" colspan="1">2287 (38.46)</td><td valign="top" align="left" rowspan="1" colspan="1">13,222 (35.62)</td><td valign="top" align="left" rowspan="1" colspan="1">964 (41.30)</td><td valign="top" align="left" rowspan="1" colspan="1">17,892 (36.42)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3 - Urgent</td><td valign="top" align="left" rowspan="1" colspan="1">189 (18.51)</td><td valign="top" align="left" rowspan="1" colspan="1">697 (25.76)</td><td valign="top" align="left" rowspan="1" colspan="1">1371 (23.05)</td><td valign="top" align="left" rowspan="1" colspan="1">9970 (26.86)</td><td valign="top" align="left" rowspan="1" colspan="1">346 (14.82)</td><td valign="top" align="left" rowspan="1" colspan="1">12,573 (25.59)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4 &#8211; Semi Urgent</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.29)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (0.59)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (0.39)</td><td valign="top" align="left" rowspan="1" colspan="1">98 (0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (0.60)</td><td valign="top" align="left" rowspan="1" colspan="1">154 (0.31)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">5 &#8211; Non-Urgent</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.02)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">4 (0.01)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">361 (35.36)</td><td valign="top" align="left" rowspan="1" colspan="1">966 (35.70)</td><td valign="top" align="left" rowspan="1" colspan="1">2164 (36.39)</td><td valign="top" align="left" rowspan="1" colspan="1">13,187 (35.53)</td><td valign="top" align="left" rowspan="1" colspan="1">993 (42.55)</td><td valign="top" align="left" rowspan="1" colspan="1">17,671 (35.97)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">1021</td><td valign="top" align="left" rowspan="1" colspan="1">2706</td><td valign="top" align="left" rowspan="1" colspan="1">5947</td><td valign="top" align="left" rowspan="1" colspan="1">37,117</td><td valign="top" align="left" rowspan="1" colspan="1">2334</td><td valign="top" align="left" rowspan="1" colspan="1">49,125</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-jchim-14-06-035"><p>The values are presented as age &#177; standard deviation and the categorial variables as total count in each group with relative percentages in brackets. Some categories did not have the requested variable assigned and they are classified as &#8220;Not assigned&#8221; line. Chi-square test is used for statistical analysis with phenobarbital as the comparison group,</p></fn><fn id="tfn2-jchim-14-06-035"><label>*</label><p>p-value &#8804;0.05,</p></fn><fn id="tfn3-jchim-14-06-035"><label>**</label><p>p-value &#8804;0.01,</p></fn><fn id="tfn4-jchim-14-06-035"><label>***</label><p>p-value &#8804;0.001.</p></fn><fn id="tfn5-jchim-14-06-035"><p>CDP, Chlordiazepoxide; DZP, diazepam; GBP, gabapentin; LRZ, lorazepam; PB, phenobarbital.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2-jchim-14-06-035" orientation="portrait"><label>Table 2</label><caption><p>The primary outcome, length of stay (LOS) in mean days &#177; standard deviation for each alcohol withdrawal protocol is presented.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Drugs</th><th valign="top" align="left" rowspan="1" colspan="1">LOS (days)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">CDP</td><td valign="top" align="left" rowspan="1" colspan="1">4.573 &#177; 5.615</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DZP</td><td valign="top" align="left" rowspan="1" colspan="1">4.084 &#177; 4.674 <xref rid="tfn8-jchim-14-06-035" ref-type="table-fn">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GBP</td><td valign="top" align="left" rowspan="1" colspan="1">5.026 &#177; 5.595 <xref rid="tfn7-jchim-14-06-035" ref-type="table-fn">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LRZ</td><td valign="top" align="left" rowspan="1" colspan="1">3.956 &#177; 4.772 <xref rid="tfn8-jchim-14-06-035" ref-type="table-fn">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PB</td><td valign="top" align="left" rowspan="1" colspan="1">4.686 &#177; 3.806</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TOTAL</td><td valign="top" align="left" rowspan="1" colspan="1">4.140 &#177; 4.866</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-jchim-14-06-035"><p>The phenobarbital group was chosen as a control for comparison with other protocols. T-test is used for statistical analysis,</p></fn><fn id="tfn7-jchim-14-06-035"><label>**</label><p>p-value &#8804;0.01,</p></fn><fn id="tfn8-jchim-14-06-035"><label>***</label><p>p-value &#8804;0.001.</p></fn><fn id="tfn9-jchim-14-06-035"><p><italic toggle="yes">CDP, Chlordiazepoxide; DZP, diazepam; GBP, gabapentin; LRZ, lorazepam; PB, phenobarbital; LOS, length of stay</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3-jchim-14-06-035" orientation="portrait"><label>Table 3</label><caption><p>Several additional secondary outcomes including heart rate, respirations, body mass index (BMI), Clinical Institute Withdrawal Assessment (CIWA) scores, and Glasgow Coma Scale (GCS) were analyzed for each drug group and mean &#177; standard deviation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">CDP</th><th valign="top" align="left" rowspan="1" colspan="1">DZP</th><th valign="top" align="left" rowspan="1" colspan="1">GBP</th><th valign="top" align="left" rowspan="1" colspan="1">LRZ</th><th valign="top" align="left" rowspan="1" colspan="1">PB</th><th valign="top" align="left" rowspan="1" colspan="1">Total Average</th><th valign="top" align="left" rowspan="1" colspan="1">Totals</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Pulse<xref rid="tfn14-jchim-14-06-035" ref-type="table-fn">&#8224;</xref></td><td valign="top" align="left" rowspan="1" colspan="1">94.23 &#177; 17.66</td><td valign="top" align="left" rowspan="1" colspan="1">92.58 &#177; 17.38</td><td valign="top" align="left" rowspan="1" colspan="1">90.05 &#177; 16.22</td><td valign="top" align="left" rowspan="1" colspan="1">92.66 &#177; 17.01</td><td valign="top" align="left" rowspan="1" colspan="1">90.82 &#177; 16.26</td><td valign="top" align="left" rowspan="1" colspan="1">92.29 &#177; 16.94</td><td valign="top" align="left" rowspan="1" colspan="1">48,139</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Respirations<xref rid="tfn14-jchim-14-06-035" ref-type="table-fn">&#8224;</xref></td><td valign="top" align="left" rowspan="1" colspan="1">17.97 &#177; 2.81</td><td valign="top" align="left" rowspan="1" colspan="1">17.70 &#177; 2.81</td><td valign="top" align="left" rowspan="1" colspan="1">17.38 &#177; 2.36</td><td valign="top" align="left" rowspan="1" colspan="1">17.67 &#177; 2.68</td><td valign="top" align="left" rowspan="1" colspan="1">17.19 &#177; 2.44</td><td valign="top" align="left" rowspan="1" colspan="1">17.62 &#177; 2.65</td><td valign="top" align="left" rowspan="1" colspan="1">48,389</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI<xref rid="tfn14-jchim-14-06-035" ref-type="table-fn">&#8224;</xref></td><td valign="top" align="left" rowspan="1" colspan="1">25.92 &#177; 4.70</td><td valign="top" align="left" rowspan="1" colspan="1">26.40 &#177; 4.97</td><td valign="top" align="left" rowspan="1" colspan="1">27.14 &#177; 5.31</td><td valign="top" align="left" rowspan="1" colspan="1">26.72 &#177; 5.08</td><td valign="top" align="left" rowspan="1" colspan="1">26.28 &#177; 4.87</td><td valign="top" align="left" rowspan="1" colspan="1">26.71 &#177; 5.09</td><td valign="top" align="left" rowspan="1" colspan="1">47,353</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CIWA</td><td valign="top" align="left" rowspan="1" colspan="1">4.78 &#177; 5.15<xref rid="tfn13-jchim-14-06-035" ref-type="table-fn">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.69 &#177; 5.72<xref rid="tfn13-jchim-14-06-035" ref-type="table-fn">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1">4.22 &#177; 5.04<xref rid="tfn13-jchim-14-06-035" ref-type="table-fn">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.94 &#177; 5.91<xref rid="tfn13-jchim-14-06-035" ref-type="table-fn">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3.53 &#177; 4.74</td><td valign="top" align="left" rowspan="1" colspan="1">5.60 &#177; 5.78</td><td valign="top" align="left" rowspan="1" colspan="1">46,732</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GCS</td><td valign="top" align="left" rowspan="1" colspan="1">14.57 &#177; 1.15</td><td valign="top" align="left" rowspan="1" colspan="1">14.61 &#177; 1.18</td><td valign="top" align="left" rowspan="1" colspan="1">14.68 &#177; 1.06</td><td valign="top" align="left" rowspan="1" colspan="1">14.53 &#177; 1.29</td><td valign="top" align="left" rowspan="1" colspan="1">14.67 &#177; 1.09</td><td valign="top" align="left" rowspan="1" colspan="1">14.56 &#177; 1.25</td><td valign="top" align="left" rowspan="1" colspan="1">24,481</td></tr></tbody></table><table-wrap-foot><fn id="tfn10-jchim-14-06-035"><p>Not all patients had data available for all outcomes. T-test is used for statistical analysis,</p></fn><fn id="tfn11-jchim-14-06-035"><label>*</label><p>p-value &#8804;0.05,</p></fn><fn id="tfn12-jchim-14-06-035"><label>**</label><p>p-value &#8804;0.01,</p></fn><fn id="tfn13-jchim-14-06-035"><label>***</label><p>p-value &#8804;0.001.</p></fn><fn id="tfn14-jchim-14-06-035"><label>&#8224;</label><p>Top and bottom 1% of sample were dropped to account for data entry errors.</p></fn><fn id="tfn15-jchim-14-06-035"><p><italic toggle="yes">CDP, Chlordiazepoxide; DZP, diazepam; GBP, gabapentin; LRZ, lorazepam; PB, phenobarbital</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t4-jchim-14-06-035" orientation="portrait"><label>Table 4</label><caption><p>The various secondary outcomes including intensive care unit (ICU) admissions, intubation rate, mortality, 30-day readmission, and alcohol induced complications were analyzed for protocol drug group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">CDP</th><th valign="top" align="left" rowspan="1" colspan="1">DZP</th><th valign="top" align="left" rowspan="1" colspan="1">GBP</th><th valign="top" align="left" rowspan="1" colspan="1">LRZ</th><th valign="top" align="left" rowspan="1" colspan="1">PB</th><th valign="top" align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>ICU Admission</bold>
<xref rid="tfn19-jchim-14-06-035" ref-type="table-fn">***</xref>
</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">293 (10.83)</td><td valign="top" align="left" rowspan="1" colspan="1">377 (6.34)</td><td valign="top" align="left" rowspan="1" colspan="1">4334 (11.68)</td><td valign="top" align="left" rowspan="1" colspan="1">201 (8.61)</td><td valign="top" align="left" rowspan="1" colspan="1">5206 (10.60)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Intubation</bold>
<xref rid="tfn19-jchim-14-06-035" ref-type="table-fn">***</xref>
</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">59 (2.18)</td><td valign="top" align="left" rowspan="1" colspan="1">61 (1.03)</td><td valign="top" align="left" rowspan="1" colspan="1">616 (1.66)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (0.99)</td><td valign="top" align="left" rowspan="1" colspan="1">759 (1.55)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Death</bold>
<xref rid="tfn18-jchim-14-06-035" ref-type="table-fn">**</xref>
</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.29)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (0.41)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (0.30)</td><td valign="top" align="left" rowspan="1" colspan="1">197 (0.53)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.13)</td><td valign="top" align="left" rowspan="1" colspan="1">232 (0.47)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Readmit</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1">
<bold>Alcohol induced complications</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Blood disorder</td><td valign="top" align="left" rowspan="1" colspan="1">164 (16.06)</td><td valign="top" align="left" rowspan="1" colspan="1">361 (13.34)</td><td valign="top" align="left" rowspan="1" colspan="1">704 (11.84)</td><td valign="top" align="left" rowspan="1" colspan="1">5019 (13.52)</td><td valign="top" align="left" rowspan="1" colspan="1">449 (19.24)</td><td valign="top" align="left" rowspan="1" colspan="1">6697 (13.63)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Drug adverse effect</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (0.77)</td><td valign="top" align="left" rowspan="1" colspan="1">349 (0.94)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">693 (1.41)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Gastrointestinal</td><td valign="top" align="left" rowspan="1" colspan="1">53 (5.19)</td><td valign="top" align="left" rowspan="1" colspan="1">169 (6.25)</td><td valign="top" align="left" rowspan="1" colspan="1">359 (6.04)</td><td valign="top" align="left" rowspan="1" colspan="1">2705 (7.29)</td><td valign="top" align="left" rowspan="1" colspan="1">356 (15.25)</td><td valign="top" align="left" rowspan="1" colspan="1">3642 (7.41)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Metabolic</td><td valign="top" align="left" rowspan="1" colspan="1">29 (2.84)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (2.03)</td><td valign="top" align="left" rowspan="1" colspan="1">132 (2.22)</td><td valign="top" align="left" rowspan="1" colspan="1">961 (2.59)</td><td valign="top" align="left" rowspan="1" colspan="1">309 (13.24)</td><td valign="top" align="left" rowspan="1" colspan="1">1486 (1.08)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Myopathy</td><td valign="top" align="left" rowspan="1" colspan="1">6 (0.59)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (0.74)</td><td valign="top" align="left" rowspan="1" colspan="1">72 (1.21)</td><td valign="top" align="left" rowspan="1" colspan="1">569 (1.53)</td><td valign="top" align="left" rowspan="1" colspan="1">297 (12.72)</td><td valign="top" align="left" rowspan="1" colspan="1">964 (1.96)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Nervous System<xref rid="tfn17-jchim-14-06-035" ref-type="table-fn">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">42 (4.11)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (3.18)</td><td valign="top" align="left" rowspan="1" colspan="1">262 (4.41)</td><td valign="top" align="left" rowspan="1" colspan="1">1572 (4.24)</td><td valign="top" align="left" rowspan="1" colspan="1">316 (13.54)</td><td valign="top" align="left" rowspan="1" colspan="1">2278 (4.64)</td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1">
<bold>Neurological condition</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Mental disorder</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (0.77)</td><td valign="top" align="left" rowspan="1" colspan="1">349 (0.94)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">693 (1.41)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Parkinson&#8217;s</td><td valign="top" align="left" rowspan="1" colspan="1">4 (0.39)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (0.59)</td><td valign="top" align="left" rowspan="1" colspan="1">71 (1.19)</td><td valign="top" align="left" rowspan="1" colspan="1">452 (1.22)</td><td valign="top" align="left" rowspan="1" colspan="1">295 (12.64)</td><td valign="top" align="left" rowspan="1" colspan="1">838 (1.71)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Traumatic Brain Injury</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (0.77)</td><td valign="top" align="left" rowspan="1" colspan="1">349 (0.94)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">693 (1.41)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Epilepsy</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">7 (0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (0.77)</td><td valign="top" align="left" rowspan="1" colspan="1">349 (0.94)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">693 (1.41)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Delirium</td><td valign="top" align="left" rowspan="1" colspan="1">12 (1.18)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (0.67)</td><td valign="top" align="left" rowspan="1" colspan="1">67 (1.13)</td><td valign="top" align="left" rowspan="1" colspan="1">599 (1.61)</td><td valign="top" align="left" rowspan="1" colspan="1">295 (12.64)</td><td valign="top" align="left" rowspan="1" colspan="1">991 (2.02)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Dementia</td><td valign="top" align="left" rowspan="1" colspan="1">1 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.30)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (0.91)</td><td valign="top" align="left" rowspan="1" colspan="1">396 (1.07)</td><td valign="top" align="left" rowspan="1" colspan="1">291 (12.47)</td><td valign="top" align="left" rowspan="1" colspan="1">750 (1.53)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Total patients in each group</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">1021</td><td valign="top" align="left" rowspan="1" colspan="1">2706</td><td valign="top" align="left" rowspan="1" colspan="1">5947</td><td valign="top" align="left" rowspan="1" colspan="1">37,117</td><td valign="top" align="left" rowspan="1" colspan="1">2334</td><td valign="top" align="left" rowspan="1" colspan="1">49,125</td></tr></tbody></table><table-wrap-foot><fn id="tfn16-jchim-14-06-035"><p>The number of patients were noted with relative percentages in brackets. Chi-square test is used for statistical analysis,</p></fn><fn id="tfn17-jchim-14-06-035"><label>*</label><p>p-value &#8804;0.05,</p></fn><fn id="tfn18-jchim-14-06-035"><label>**</label><p>p-value &#8804;0.01,</p></fn><fn id="tfn19-jchim-14-06-035"><label>***</label><p>p-value &#8804;0.001.</p></fn><fn id="tfn20-jchim-14-06-035"><p><italic toggle="yes">CDP, Chlordiazepoxide; DZP, diazepam; GBP, gabapentin; LRZ, lorazepam; PB, phenobarbital</italic>.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>